However, alpelisib with letrozole for the neoadjuvant treatment of HR+/HER2– early breast cancer patients reported no improvement in ORR regardless of whether the patients have PIK3CA mutation (Mayer et al., 2019). This evidence concerns the gene ERBB2 and breast carcinoma.